Riskpilot← Back to searchSign inGet full accessNORDIC LABORATORIES AS
ASActiveOrg 925666033Skippergata 14A, 9008 TromsøMedisinske laboratorietjenester · NACE 86906Est. 20200 employees
Revenue 2024
NOK 0
EBITDA margin
—
-32% vs 2023
Equity ratio
88.2%
Financial strength
Net profit 2024
NOK -28K
-16% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -28K | -32% |
| Net profit | NOK -28K | -16% |
| Total assets | NOK 33K | -42% |
| Equity | NOK 29K | -49% |
| Employees | 0 | — |
Legal name
NORDIC LABORATORIES AS
Org number
925666033
Legal form
Aksjeselskap
NACE code
86906 · Medisinske laboratorietjenester
Founded
21. september 2020
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Utføre medisinske undersøkelser, herunder utføre prøver og klinisk-kjemiske analyser. Salg av produkter tilknyttet klinisk-kjemisk analyse samt delta i andre foretak med tilsvarende virksomhet.
Address
Skippergata 14A, 9008 Tromsø
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 285 | 179 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | 98 | −12 | −21 | −28 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 98 | −12 | −21 | −28 |
| Net financials | 0 | −4 | −4 | 0 | −0 |
| Profit before tax | 0 | 94 | −15 | −21 | −28 |
| Tax | −0 | 18 | −3 | 3 | −0 |
| Net profit | 0 | 76 | −12 | −24 | −28 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 30 | 528 | 81 | 57 | 33 |
| Equity | 17 | 93 | 81 | 57 | 29 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 434 | 0 | 0 | 4 |
| Total debt | 13 | 434 | 0 | 0 | 4 |
EBITDA margin
-2778500.0%
This company
15.8%
Market median
-17585543% vs market
20202024
Equity ratio
88.2%
This company
38.2%
Market median
+131% vs market
20202024
Return on equity
-96.9%
This company
18.4%
Market median
-627% vs market
20202024
Net profit margin
-2810000.0%
This company
8.1%
Market median
-34691458% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-09-09 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RS Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Rsb Holding Aps | Company | 50% | 50% | 2022 |
| Company | 50% | 50% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDIC LABORATORIES AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rune Skovmand Bosselmann | Chief Executive Officer | 0 companies |
| Øivind Snorre Vassbotn | Chairman | 0 companies |